SCHEMBL1970345

SCHEMBL1970345

CCCc1nc(C(C)(C)O)c(C(=O)O)n1Cc1ccc(-c2ccccc2C2(C(c3ccccc3)(c3ccccc3)c3ccccc3)N=NN=N2)cc1

nearest known ligand 0.68

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
AGTR1 P30556 2/20 0.61
AGTR2 P50052 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL2576561 0.99 AGTR1 (0.60) AGTR1AGTR2
SCHEMBL3342427 0.99 AGTR1 (0.60) AGTR1AGTR2
SCHEMBL7308729 0.95 AGTR2 (0.55) AGTR1AGTR2
SCHEMBL7303815 0.93 AGTR1 (0.52) AGTR1AGTR2
SCHEMBL8845378 0.93 AGTR1 (0.51) AGTR1AGTR2
SCHEMBL1988060 0.91 AGTR1 (0.53) AGTR1AGTR2
SCHEMBL7308562 0.89 AGTR1 (0.47) AGTR1AGTR2
SCHEMBL7886538 0.89 AGTR1 (0.48) AGTR1AGTR2
SCHEMBL7304485 0.88 AGTR1 (0.53) AGTR1
SCHEMBL7297184 0.88 AGTR1 (0.50) AGTR1AGTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1910343-B1 PROCESS FOR THE PREPARATION OF OLMESARTAN MEDOXOMIL KRKA (SI) 2014-10-29 EP claimed
CN-110396084-B Method for preparing high-purity trityl olmesartan medoxomil 连云港润众制药有限公司 2023-01-20 CN disclosed
US-8076492-B2 Process for preparing trityl olmesartan medoxomil and olmesartan medoxomil CIPLA LIMITED (IN) 2011-12-13 US disclosed
US-8048904-B2 Process for the preparation of olmesartan medoxomil MATRIX LABORATORIES LTD. (IN) 2011-11-01 US disclosed
EP-2334668-A1 PROCESS FOR PREPARING OLMESARTAN MEDOXOMIL INTERMEDIATE Krka Tovarna Zdravil, D.D., Novo Mesto (SI) 2011-06-22 EP disclosed
US-20100160643-A1 Process for Preparing Trityl Olmesartan Medoxomil and Olmesartan Medoxomil CIPLA LIMITED (IN) 2010-06-24 US disclosed
WO-2010026255-A1 PROCESS FOR PREPARING OLMESARTAN MEDOXOMIL INTERMEDIATE KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO (SI) 2010-03-11 WO disclosed
US-20090281327-A1 PROCESS FOR THE PREPARATION OF OLMESARTAN MEDOXOMIL MATRIX PHARMACORP PRIVATE LIMITED (IN) 2009-11-12 US disclosed
EP-2074116-A2 PROCESS FOR PREPARING TRITYL OLMESARTAN MEDOXOMIL AND OLMESARTAN MEDOXOMIL Cipla Limited (IN) 2009-07-01 EP disclosed
WO-2008043996-A2 PROCESS FOR PREPARING TRITYL OLMESARTAN MEDOXOMIL AND OLMESARTAN MEDOXOMIL CIPLA LIMITED (IN) 2008-04-17 WO disclosed
EP-0503785-B1 1-Biphenylimidazole derivatives, their preparation and their therapeutic use SANKYO CO (JP) 2001-04-25 EP disclosed
US-5646171-A HYPOTENSIVE AGENTS SANKYO COMPANY, LIMITED (JP) 1997-07-08 US disclosed
US-5616599-A HYPOTENSIVE AGENTS FOR CARDIOVASCULAR DISORDER SANKYO COMPANY, LIMITED (JP) 1997-04-01 US disclosed
EP-0503785-A1 1-Biphenylimidazole derivatives, their preparation and their therapeutic use Sankyo Company Limited (JP) 1992-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160643-A1 Process for Preparing Trityl Olmesartan Medoxomil and Olmesartan Medoxomil MED1, AGTR1, MED12 AGTR1 2/4885AGTR2 4/4885
US-20090281327-A1 PROCESS FOR THE PREPARATION OF OLMESARTAN MEDOXOMIL MED1, TET1, AGTR1 AGTR1 3/4885AGTR2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.